NO951212L - Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus - Google Patents

Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus

Info

Publication number
NO951212L
NO951212L NO951212A NO951212A NO951212L NO 951212 L NO951212 L NO 951212L NO 951212 A NO951212 A NO 951212A NO 951212 A NO951212 A NO 951212A NO 951212 L NO951212 L NO 951212L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
immunodeficiency virus
human
antibodies against
neutralizing monoclonal
Prior art date
Application number
NO951212A
Other languages
English (en)
Norwegian (no)
Other versions
NO951212D0 (no
Inventor
Dennis R Burton
Carlos F Barbas
Richard A Lerner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO951212D0 publication Critical patent/NO951212D0/no
Publication of NO951212L publication Critical patent/NO951212L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO951212A 1992-09-30 1995-03-29 Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus NO951212L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95414892A 1992-09-30 1992-09-30
PCT/US1993/009328 WO1994007922A1 (fr) 1992-09-30 1993-09-30 Anticorps monoclonaux neutralisateurs humains contre le virus de l'immunodeficience humaine

Publications (2)

Publication Number Publication Date
NO951212D0 NO951212D0 (no) 1995-03-29
NO951212L true NO951212L (no) 1995-05-29

Family

ID=25495000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951212A NO951212L (no) 1992-09-30 1995-03-29 Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus

Country Status (10)

Country Link
EP (1) EP0675904B1 (fr)
JP (1) JPH08502260A (fr)
AT (1) ATE233814T1 (fr)
AU (1) AU681360B2 (fr)
CA (1) CA2145757A1 (fr)
DE (1) DE69332744T2 (fr)
ES (1) ES2194015T3 (fr)
FI (1) FI951488A (fr)
NO (1) NO951212L (fr)
WO (1) WO1994007922A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243745T1 (de) 1994-01-31 2003-07-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
EP1091763B1 (fr) * 1998-06-29 2003-09-17 Wolfgang Bergter Medicaments antiviraux et antiretroviraux radioimmunologiques a base d'emetteurs de rayonnement alpha et beta
CA2358385C (fr) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
CA2406236C (fr) 2000-04-17 2013-02-19 Dyax Corp. Nouvelles methodes de construction de bibliotheques de materiels genetiques representant les membres d'une famille diversifiee de peptides, de polypeptides ou de proteines
PT2316940E (pt) 2000-12-18 2013-10-16 Dyax Corp Bibliotecas orientadas de pacotes genéticos
AU2002254382B2 (en) 2001-03-22 2007-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant and nonglycosylated cyanovirins
EP1411770A4 (fr) 2001-07-05 2006-05-10 Chiron Corp Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
WO2003033666A2 (fr) 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4
CA2485120C (fr) 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification de nouveaux anticorps monoclonaux humains de neutralisation a activite sensiblement croisee contre le virus vih-1
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CA2585574A1 (fr) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Anticorps monoclonaux humains a reaction antigenique croisee large neutralisant generalement vih-1
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009114815A1 (fr) 2008-03-13 2009-09-17 Dyax Corp Bibliothèques de boîtiers génétiques comprenant de nouvelles conceptions de hc cdr3
ES2528963T3 (es) 2008-04-24 2015-02-13 Dyax Corp. Bibliotecas de paquetes genéticos que comprenden nuevos diseños de CDR1, CDR2, y CDR3 de HC y nuevos diseños de CDR1, CDR2, y CDR3 de LC
CN105734678B (zh) 2010-07-16 2019-11-05 阿迪马布有限责任公司 合成多核苷酸文库
EP2492279A1 (fr) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Procédé de sélection rapide d'immunogène par expression à la surface du lentivirus.
EP2698377A1 (fr) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Procédé de sélection rapide d'immunogène de variants de la GP-120 du VIH amélioré
AR114560A1 (es) * 2017-11-17 2020-09-23 Grifols Diagnostic Solutions Inc Proteínas antigénicas de la envoltura del virus de inmunodeficiencia humano expresadas en mamíferos
IL294218A (en) 2019-12-27 2022-08-01 Chiome Bioscience Inc Antibody against cdcp1
WO2022049867A1 (fr) 2020-09-02 2022-03-10 国立大学法人東京大学 Régulateur de microenvironnement immunitaire tumoral et son utilisation préventive, thérapeutique ou de diagnostic
CN112521492B (zh) * 2020-12-18 2022-05-20 杭州贤至生物科技有限公司 乙肝表面抗原单克隆抗体的制备

Also Published As

Publication number Publication date
NO951212D0 (no) 1995-03-29
ATE233814T1 (de) 2003-03-15
JPH08502260A (ja) 1996-03-12
EP0675904A4 (fr) 1996-08-21
AU5350194A (en) 1994-04-26
FI951488A0 (fi) 1995-03-29
ES2194015T3 (es) 2003-11-16
DE69332744T2 (de) 2004-01-15
CA2145757A1 (fr) 1994-04-14
FI951488A (fi) 1995-05-23
DE69332744D1 (de) 2003-04-10
EP0675904B1 (fr) 2003-03-05
EP0675904A1 (fr) 1995-10-11
AU681360B2 (en) 1997-08-28
WO1994007922A1 (fr) 1994-04-14

Similar Documents

Publication Publication Date Title
NO951212L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
ATE405679T1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
NO950881D0 (no) Nöytraliserende monoklonale menneske-antistoffer mot andedretts-syncytial-virus
FI924819A0 (fi) Chimaera anti-icam-i-antikroppar foer maenniskobruk, foerfaranden foer deras framstaellning samt deras anvaendning
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE427488T1 (de) Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion
ES2067866T3 (es) Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.
BRPI9709524B8 (pt) processo para a produção de um anticorpo para células t que expressam cd4
FI873410A (fi) Kahden uuden hybridooman tuottamia apolipoproteiini-B-spesifisiä monoklonaalisia vasta-aineita
WO2004009785A3 (fr) Proteine de fusion igg fc/hiv-gp120/c3d
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
ATE132502T1 (de) Peptide, die epitope auf r-ifn-beta repräsentieren, antikörper dagegen, und ihre anwendung
ES2061655T3 (es) Un procedimiento para cultivar un hibridoma humano/humano productor de anticuerpos monoclonales humanos.
ATE128733T1 (de) Monoklonale antikörper gegen hiv gp120.
DE69617255T2 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ES2051870T3 (es) Anticuerpo monoclonal capaz de suprimir la proliferacion de linfocitos t.
IT7919222A0 (it) Procedimento per produrre anticorpi umani.
FI850484L (fi) Diagnostiskt foerfarande, vid vilket man utnyttjar en ny monoklonal antikropp specifik mot maenniskans t-cellers antigen.